Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Indacaterol versus placebo with open-label tiotropium active control in COPD
2005-004169-41Phase 3Completed
- Sponsor
- Novartis
- Start
- Dec 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of indacaterol in chronic obstructive pulmonary disease (COPD) (4 arms), sponsored by Novartis. Primary endpoint: Trough FEV1 at 12 weeks. Started Dec 2005; status: completed.
02
Drugs
indacaterol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2005-004169-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-004169-41.